{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-22-000098","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.551876+00:00","generated_at":"2026-06-22T20:04:05.841652+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pfizer Q3 revenue $22.6B (-6% YoY); Adj. EPS $1.78 (+40%); raises FY2022 guidance","bullets":["Reported diluted EPS $1.51 (+6%); Adjusted diluted EPS $1.78 (+40%) YoY.","Paxlovid contributed $7.5B in Q3; Comirnaty revenue guidance raised to ~$34B for 2022.","FY2022 revenue guidance raised to $99.5-102.0B; Adj. EPS guidance raised to $6.40-6.50.","Completed Biohaven ($12.8B) and GBT ($5.6B) acquisitions early Q4 2022.","Positive Phase 3 readouts for RSV vaccine, Prevnar 20 in pediatrics, and Talzenna/Xtandi combo."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-22-000098","json":"https://secwatch.observer/filing/0000078003-22-000098.json","markdown":"https://secwatch.observer/filing/0000078003-22-000098.md","text":"https://secwatch.observer/filing/0000078003-22-000098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800322000098/0000078003-22-000098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800322000098/pfe-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T20:04:05.841652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d630746df042005f6cbdfe966b609b12a955c6c","claim":"PFIZER INC reported the third quarter of 2022 results: revenue $22,638, net income 8,608, EPS $1.51. Guidance raised.","evidence_excerpt":"months of 2022 and 2021 (5) are summarized below. OVERALL RESULTS ($ in millions, except per share amounts) Third-Quarter Nine Months 2022 2021 Change 2022 2021 Change Revenues $ 22,638 $ 24,035 (6%) $ 76,040 $ 57,450 32% Reported Net Income (2) 8,608 8,146 6% 26,378 18,586 42% Reported Diluted EPS (2) 1.51 1.42 6% 4.60 3.27 41% Adjusted Income (3) 10,172 7,279","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800322000098/0000078003-22-000098-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"$22,638"},{"label":"Net income","value":"8,608"},{"label":"EPS","value":"$1.51"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}